Alkermes Sustainability Profile
Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.
DitchCarbon Score
How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkermes's score of 30 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkermes's reported carbon emissions
In 2024, Alkermes reported total carbon emissions of approximately 20,000,000 kg CO2e, a reduction from about 25,000,000 kg CO2e in 2023 and 30,000,000 kg CO2e in 2022. The emissions data for 2021 indicates a total of about 33,000,000 kg CO2e, which included 15,045,000 kg CO2e from Scope 1 and 17,954,000 kg CO2e from Scope 2 emissions. This demonstrates a significant downward trend in emissions over the past few years. Alkermes has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organization, indicating that it operates independently in its reporting and commitments. The company’s emissions per employee were reported at approximately 10,000 kg CO2e in 2024, down from about 15,000 kg CO2e in 2023. Additionally, emissions per million dollars of revenue were approximately 0.00001 kg CO2e in 2024, reflecting a commitment to improving efficiency alongside revenue growth. Overall, Alkermes is making strides in reducing its carbon footprint, with a clear focus on decreasing emissions year-on-year, although specific reduction targets have not been established.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,960,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 17,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
How Carbon Intensive is Alkermes's Industry?
How Carbon Intensive is Alkermes's Location?
Alkermes's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alkermes has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
